LabCorp Ventures

Amal Abouelenein serves as Vice President of Ventures & Strategic Partnerships and leads the unit's investment decisions. The ventures function reports through LabCorp's CFO office, aligning capital deployment with corporate strategy rather than operating as an independent partnership. Investment committee composition beyond Abouelenein has not been publicly detailed.

Sourcing leans heavily on LabCorp's clinical operations. The company's network of 1,700+ patient service centers and relationships with 800,000+ ordering physicians surface companies whose technologies intersect with diagnostic workflows. De-identified data from millions of lab results also helps the unit identify emerging testing categories and technologies before they appear on traditional VC radars. The unit also co-invests alongside healthcare-focused funds that refer portfolio companies for clinical validation partnerships.

LabCorp Ventures and Quest Diagnostics' corporate venture arm operate independently, but they frequently co-invest in the same rounds—particularly in companies building diagnostic tools that are lab-network-agnostic. The two parent companies are primary competitors in US clinical testing, and their venture units occasionally sit on opposite sides of a table, but they have co-invested alongside each other when strategic alignment overlaps.